[Daratumumab (newly diagnosed multiple myeloma, ineligible for stem cell transplant) – Addendum to Project A25-108]

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018015088
German
Original Title: Daratumumab (neu diagnostiziertes multiples Myelom, Stammzelltransplantation nicht geeignet ) – Addendum zum Projekt A25-108
Details
Project Status: Completed
URL for project: https://www.iqwig.de/projekte/a26-02.html
Year Published: 2026
URL for published report: https://www.iqwig.de/download/a26-02_daratumumab_addendum-zum-projekt-a25-108_v1-0.pdf
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
DOI: https://doi.org/10.60584/A26-02
MeSH Terms
  • Multiple Myeloma
  • Bortezomib
  • Lenalidomide
  • Dexamethasone
  • Antibodies, Monoclonal
  • Antineoplastic Agents
Keywords
  • Daratumumab
  • Bortezomib
  • Lenalidomide
  • Dexamethasone
  • Multiple Myeloma
  • Benefit Assessment
  • NCT03652064
Contact
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.